Consano Bio is a biotech developing C-1101, a biologic therapy for chronic sciatica caused by lumbosacral radiculopathy. It serves patients with chronic nerve pain whose existing options have failed or are inadequate. The candidate is positioned to be the first non-opioid pharmaceutical that modifies the underlying disease rather than masking pain.
acquisitions n=0
No cited completed company acquisition recorded.
traction n=0
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
valuations n=0
No cited valuation with an explicit basis is recorded.
revenue multiples n=0
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.